Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.920
-0.070 (-3.52%)
Aug 1, 2025, 4:00 PM - Market closed
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Revance Therapeutics stock has a target of 8.00, which predicts a 316.67% increase from the current stock price of 1.92.
Price Target: $8.00 (+316.67%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 3, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Revance Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +316.67% | Apr 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $8 | Strong Buy | Maintains | $5 → $8 | +316.67% | Jan 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +160.42% | Sep 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +160.42% | Jul 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +160.42% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
9.69M
from 103.20K
Increased by 9,289.17%
Revenue Next Year
13.26M
from 9.69M
Increased by 36.84%
EPS This Year
-0.71
from -0.74
EPS Next Year
-0.82
from -0.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 22.1M | 18.9M | ||
| Avg | 9.7M | 13.3M | 9.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20,248.0% | 127.6% | 42.5% | ||
| Avg | 9,289.2% | 36.8% | -30.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.54 | -0.63 | -1.13 |
| Avg | -0.71 | -0.82 | -1.23 |
| Low | -0.81 | -1.01 | -1.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.